Skip to main content

BENOXINATE Uses, Side Effects, and More

 BENOXINATE


BRAND NAME:- BENDZON 0.4% eyedrops.


BENOXINATE is also known as Oxybuprocaine. It is a good surface anaesthetic for the eye ; has little irritancy. A 0.4% solution rapidly produced corneal anaesthesia sufficient for tonometry without causing mydriasis or corneal damage.

PHARMACODYNAMIC:- 

BENOXINATE is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine. 

PHARMACOKINETICS:-

Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.


MECHANISM OF ACtion:-

BENOXINATE binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses. 

USED:- 

A local anesthetic, which is used especially in ophthalmology and otolaryngology.


SIDE EFFECTS:-

Allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue. changes in vision.


 DOSE:- DIRECTION BY PHYSICIAN.

Labels:

Comments

Post a Comment

Popular posts from this blog

Cefpodoxime proxetil Uses, Side Effects, and More

 Cefpodoxime proxetil Brand name:- cefoprox ,cepodem,DOXCEF 100,200mg cap.  Cefpodoxime Proxetil is an antibiotic. It kills the bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive. Pharmacodynamic:-  Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action:-  Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicilli
Post a Comment
Read more

Cephalexin ( ZYD ) ( Cefalexin ) Uses, Side Effects, and More

 Cephalexin (ZYD) (Cefalexin) Brand name:-  Cephacillin 250,500mg cap; Sporidex, Alcephin,Cephaxin cap. Cephalexin (also called Cefalexin)  is the most common used orally effective first generation cephalosporin , similar in spectrum to cefazolin , but less active against penicillinase producing staphylococci and H. Influenza. Plasma protein binding is low; it attains High concentration in bile and is excreted unchanged in urine; t½ - 60min. Pharmacodynamic:-  Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.Label It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis. Pharmacokinetics:- Cephalexin is rapidly and almost completely absorbed from t
Post a Comment
Read more

BASILIXIMAB Uses, Side Effects, and More

 BASILIXIMAB BRAND NAME:- Simulect   BASILIXIMAB is another anti CD - 25 antibody with higher affinity for the IL-2 receptor, but shorter plasma t½ (1 week) . is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. PHARMACODYNAMIC:- Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.  MECHANISM OF ACTION:-  Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the trans
1 comment
Read more